New drug cocktail shows promise against deadly thyroid cancer before surgery
NCT ID NCT04675710
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tests whether giving three drugs (pembrolizumab, dabrafenib, and trametinib) before surgery can help control a rare and aggressive thyroid cancer called anaplastic thyroid cancer that has a specific gene change (BRAF V600E). The goal is to make surgery more successful and improve survival. About 30 adults with this cancer will receive the drug combination before their operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55901, United States
-
Stanford School of Medicine
Stanford, California, 94304, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.